

Edgar Filing: CEL SCI CORP - Form 8-K

CEL SCI CORP  
Form 8-K  
April 02, 2015

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K  
-----

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2, 2015

CEL-SCI CORPORATION  
-----

(Exact name of registrant as specified in its charter)

|   |                       |                                      |
|---|-----------------------|--------------------------------------|
| Colorado  | 001-11889             | 84-0916344                           |
| -----   | -----                 | -----                                |
| (State or other jurisdiction<br>of incorporation) | (Commission File No.) | (IRS Employer<br>Identification No.) |

8229 Boone Blvd. #802  
Vienna, VA 22182  
-----

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460  
-----

N/A  
-----

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CEL SCI CORP - Form 8-K

Item 8.01 Other Events.

The following is an update regarding the pending arbitration proceeding CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC and PharmaNet GmbH (f/k/a PharmaNet AG):

CEL-SCI initially retained inVentiv, a clinical research organization, to conduct the Phase III Clinical Trial of CEL-SCI's investigational drug Multikine(C) (Leukocyte Interleukin, Injection). CEL-SCI terminated inVentiv in or about March 2013 and replaced it with two clinical research organizations, Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd. CEL-SCI's arbitration claim is initiated under the Commercial Rules of the American Arbitration Association, pursuant to the parties' contract, and alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. In an amended statement of claim, CEL-SCI has also alleged professional malpractice against inVentiv. CEL-SCI seeks at least \$50 million in damages.

inVentiv, which previously asserted (i) a breach of contract counterclaim against CEL-SCI, seeking at least \$2 million in damages for services allegedly performed by inVentiv, has alleged additional counterclaims against CEL-SCI, for (ii) breach of contract, seeking at least \$1 million in damages for allegedly using inVentiv's name in connection with publications and promotions, which inVentiv claims breached a provision in the parties' contract; (iii) opportunistic breach, restitution and unjust enrichment, seeking at least \$20 million in disgorgement of alleged unjust profits allegedly made by CEL-SCI as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking at least \$1 million in damages for allegedly defamatory statements made about inVentiv. CEL-SCI believes inVentiv's counterclaims are meritless and intends to vigorously defend against them.

As a result, the arbitration hearing (the arbitration equivalent of a trial), which was previously scheduled for May 4, 2015, has been tentatively rescheduled for October 27, 2015 through November 17, 2015. The arbitrator has instructed the parties to hold this time period free on their calendars.

Although the arbitrator has allowed both parties to supplement their claims, inVentiv has moved to dismiss CEL-SCI's additional claim for professional malpractice, which CEL-SCI will vigorously oppose.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 2, 2015

CEL-SCI CORPORATION

By: /s/ Patricia B. Prichep

-----  
Patricia B. Prichep

Edgar Filing: CEL SCI CORP - Form 8-K

Senior Vice President of Operations